Spherix Expands Phase 3 Naturlose Diabetes Trial Outside Of

Posted: Wed Jul 16, 2008 8:18 am

Spherix Incorporated (Nasdaq: SPEX) reported that the Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), will expand outside of the United States. Several countries with high prevalence of treatment-naive type II diabetics are being considered. "This expansion abroad should allow us to finish enrollment in the first quarter of 2009, which is consistent with the timeline reported at the recent Shareholders Meeting.

Read more...